2. Academic Validation
  3. Targeting EphA2 in cancer

Targeting EphA2 in cancer

  • J Hematol Oncol. 2020 Aug 18;13(1):114. doi: 10.1186/s13045-020-00944-9.
Ta Xiao 1,  Yuhang Xiao 2,  Wenxiang Wang 3 4,  Yan Yan Tang 4,  Zhiqiang Xiao 5,  Min Su 6 7
Affiliations

Affiliations

  • 1 Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu, 210042, China.
  • 2 Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
  • 3 Thoracic Surgery Department 2, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
  • 4 Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
  • 5 Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. [email protected].
  • 6 Thoracic Surgery Department 2, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China. [email protected].
  • 7 Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China. [email protected].
PMID: 32811512 DOI: 10.1186/s13045-020-00944-9
Abstract

Eph Receptors and the corresponding Eph receptor-interacting (ephrin) ligands jointly constitute a critical cell signaling network that has multiple functions. The tyrosine kinase EphA2, which belongs to the family of Eph Receptors, is highly produced in tumor tissues, while found at relatively low levels in most normal adult tissues, indicating its potential application in Cancer treatment. After 30 years of investigation, a large amount of data regarding EphA2 functions have been compiled. Meanwhile, several compounds targeting EphA2 have been evaluated and tested in clinical studies, albeit with limited clinical success. The present review briefly describes the contribution of EphA2-ephrin A1 signaling axis to carcinogenesis. In addition, the roles of EphA2 in resistance to molecular-targeted agents were examined. In particular, we focused on EphA2's potential as a target for Cancer treatment to provide insights into the application of EphA2 targeting in Anticancer strategies. Overall, EphA2 represents a potential target for treating malignant tumors.

Keywords

Cancer; EphA2 receptor; Ephrin A1; Target; Therapy.

Figures